AU2001270300A1 - Drug delivery formulations and targeting - Google Patents

Drug delivery formulations and targeting

Info

Publication number
AU2001270300A1
AU2001270300A1 AU2001270300A AU7030001A AU2001270300A1 AU 2001270300 A1 AU2001270300 A1 AU 2001270300A1 AU 2001270300 A AU2001270300 A AU 2001270300A AU 7030001 A AU7030001 A AU 7030001A AU 2001270300 A1 AU2001270300 A1 AU 2001270300A1
Authority
AU
Australia
Prior art keywords
targeting
drug delivery
delivery formulations
formulations
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270300A
Inventor
Edward B. Brown
Robert B. Campbell
Dai Fukumura
Rakesh K Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2001270300A1 publication Critical patent/AU2001270300A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/806—Virus-based particle with exterior chemical attachment
    • Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
AU2001270300A 2000-07-06 2001-07-05 Drug delivery formulations and targeting Abandoned AU2001270300A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21617300P 2000-07-06 2000-07-06
US60216173 2000-07-06
PCT/US2001/021183 WO2002003959A1 (en) 2000-07-06 2001-07-05 Drug delivery formulations and targeting

Publications (1)

Publication Number Publication Date
AU2001270300A1 true AU2001270300A1 (en) 2002-01-21

Family

ID=22806004

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270300A Abandoned AU2001270300A1 (en) 2000-07-06 2001-07-05 Drug delivery formulations and targeting

Country Status (3)

Country Link
US (1) US6680068B2 (en)
AU (1) AU2001270300A1 (en)
WO (1) WO2002003959A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
DE10214983A1 (en) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Nebulisable liposomes and their use for pulmonary application of active substances
DK2286795T3 (en) * 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
CA2490959C (en) 2002-07-02 2013-04-16 Board Of Regents, The University Of Texas System Radiolabeled compounds and liposomes and their methods of making and using the same
US8088605B2 (en) * 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
WO2005079185A2 (en) * 2003-09-02 2005-09-01 Board Of Regents, The University Of Texas System Neutral liposome-encapsulated compounds and methods of making and using thereof
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
CN101065114A (en) * 2004-04-01 2007-10-31 特瓦制药工业有限公司 Imroved formulations of 6-mercaptopurine
WO2006002538A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
US20060051406A1 (en) * 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
US20060159738A1 (en) * 2004-12-14 2006-07-20 Applera Corporation Cationic liposomes and methods of use
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
AU2006339072A1 (en) * 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
US20070071683A1 (en) * 2005-09-27 2007-03-29 The Regents Of The University Of California Ultrasonic concentration of carrier particles
US7838658B2 (en) * 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007111720A2 (en) * 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
MX2008014953A (en) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer.
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20100047334A1 (en) * 2006-10-06 2010-02-25 Sofou Stavroula Ph sensitive liposome compositions for controlling surface topography and binding reactivity in functionalized liposomes
US8067390B2 (en) * 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
WO2009091531A2 (en) * 2008-01-16 2009-07-23 The General Hospital Corporation Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
WO2009129395A1 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
US20090263482A1 (en) * 2008-04-18 2009-10-22 Vered Rosenberger Treatment of inflammatory bowel disease with 6-mercaptopurine
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
DE102009031274A1 (en) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomes for pulmonary application
EP2449106B1 (en) 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
US8716464B2 (en) * 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
MX339050B (en) 2009-12-18 2016-05-09 Novartis Ag Organic compositions to treat hsf1-related diseases.
JP2013519869A (en) 2010-02-10 2013-05-30 ノバルティス アーゲー Methods and compounds for muscle growth
BR112012024884A2 (en) 2010-03-31 2016-10-18 Gilead Pharmasset Llc stereo-selective synthesis of phosphorus-containing assets
UY33312A (en) 2010-03-31 2011-10-31 Pharmasset Inc PURINE NUCLEOSIDE PHOSPHORAMIDATE
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
DK2561077T3 (en) 2010-04-23 2016-08-01 Arrowhead Res Corp Organic compositions for the treatment of beta-ENaC-related diseases
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
WO2012119095A1 (en) 2011-03-02 2012-09-07 Board Of Regents, The University Of Texas System Fus1/tusc2 therapies
JP2014525435A (en) 2011-09-02 2014-09-29 ノバルティス アーゲー Organic composition for treating HSF1-related diseases
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
WO2013114377A1 (en) * 2012-02-02 2013-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Stable liposomes for drug delivery
MX2014013367A (en) 2012-05-02 2014-12-08 Novartis Ag Organic compositions to treat kras-related diseases.
CN110464709A (en) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 For treating the neuroprotective liposome composition and method of apoplexy
EP2961843A2 (en) 2013-02-28 2016-01-06 Arrowhead Research Corporation Organic compositions to treat epas1-related diseases
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
WO2015051135A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compositions to treat hepcidin-related diseases
WO2016011123A1 (en) 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
CN107812197B (en) * 2014-09-20 2018-09-18 中国药科大学 A kind of inflammation targeted neutrophil leucocyte delivery system and its application
EP3227446A1 (en) 2014-12-01 2017-10-11 Novartis AG Compositions and methods for diagnosis and treatment of prostate cancer
FR3031669B1 (en) * 2015-01-19 2020-01-31 Ninapharm ADVANCED DELIVERY SYSTEM (ADS)
CN107529972B (en) * 2015-04-30 2020-04-21 索尼奥林巴斯医疗解决方案公司 Signal processing device and medical observation system
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CN108601765A (en) 2015-12-18 2018-09-28 德克萨斯州大学系统董事会 Therapeutic agent for premature labor management
WO2018047148A1 (en) 2016-09-12 2018-03-15 Novartis Ag Compounds for the inhibition of mirna
CN116672456A (en) 2016-10-12 2023-09-01 得克萨斯州大学系统董事会 Methods and compositions for TUSC2 immunotherapy
CN106581695A (en) * 2016-10-27 2017-04-26 山东省分析测试中心 Cationic liposome, preparation method and applications thereof
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
EP3655004A2 (en) 2017-07-21 2020-05-27 Novartis AG Compositions and methods to treat cancer
CA3074303A1 (en) 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
US20210123016A1 (en) 2018-05-02 2021-04-29 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
EP3870700A1 (en) 2018-10-24 2021-09-01 Codiak BioSciences, Inc. Methods to improve potency of electroporation
KR20210125530A (en) 2019-02-08 2021-10-18 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Telomerase-containing exosomes for the treatment of diseases associated with aging and age-related organ dysfunction
WO2021216541A1 (en) 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
WO2022040435A1 (en) 2020-08-19 2022-02-24 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
CN114831940B (en) * 2022-05-11 2023-10-31 南通大学 Drug carrying system for carrying anticancer drug and preparation method and application thereof
WO2023225160A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839175A (en) 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes

Also Published As

Publication number Publication date
US20020090392A1 (en) 2002-07-11
WO2002003959A1 (en) 2002-01-17
US6680068B2 (en) 2004-01-20

Similar Documents

Publication Publication Date Title
AU2001270300A1 (en) Drug delivery formulations and targeting
AU2001264887A1 (en) Drug delivery device
AU2002241538A1 (en) Intrasvascular drug delivery device and use therefor
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
AU2001238386A1 (en) Medication delivery devices
AU2001235009A1 (en) Drug delivery apparatus
AU2002341959A1 (en) Drug delivery devices and methods
AU4357800A (en) Intracellular pharmaceutical targeting
AU3403201A (en) Drug delivery device and method
AU2123200A (en) Drug delivery device
AU4985600A (en) Drug delivery device
AU2002239397A1 (en) Drug formulation having improved oral tolerability
HK1049438B (en) Sub-tenon drug delivery
AU2002330273A1 (en) Liposome-encapsulated insulin formulations
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU4947100A (en) Drug delivery device
IL152593A0 (en) Liposome drug delivery
AU2001289102A1 (en) Topical formulations for delivery of interleukin-11
AU2001270963A1 (en) Transdermal drug delivery system
AU2001243515A1 (en) Combination drug therapy
AU2002243290A1 (en) Transluminal drug delivery catheter
AU2001232244A1 (en) Drug comprising combination
AU2002219249A1 (en) Enteric-coated drug formulations and their manufacture
AU6503399A (en) Drug delivery catheter
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery